No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Hunan Jiudian Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that spans the entire value chain from drug discovery and development to manufacturing and commercialization. The company's extensive product line includes medications for treating allergies, infections, and inflammatory conditions, as well as analgesics and gynecological remedies. Their offerings further extend to products for digestive health, both Western chemical drugs and traditional Chinese patent medicines, medical equipment, and Active Pharmaceutical Ingredients (APIs). Additionally, Hunan Jiudian provides contract manufacturing services for various pharmaceutical formulations, such as tablets, capsules, granules, and oral liquid preparations like solutions and syrups. The company is headquartered in Changsha, China.
www.hnjiudian.comNo one on the platform currently holds 300705.SZ.
No tracked institution reports a position in 300705.SZ as of their last filing.
No one on the platform has traded 300705.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 17.9% | 19.2% | 16.3% | — | — | — |
| Rev. Growth % | 6.1% | 26.0% | ||||
| Profit Margin % | 15.2% | 14.1% | 12.1% | |||
| Free Cash Flow Margin % | -0.2% | 1.9% | -1.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.8B | -13.5% | $0.59 | $0.34–$0.84 | — | 2 |
| 2027 | $3.4B | +19.4% | $0.74 | $0.74–$0.74 | — | 1 |
| 2028 | $4.1B | +20.2% | $0.97 | $0.97–$0.97 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300705.SZHunan Jiudian Pharmaceutical Co., Ltd. | $10.44 | -0.38% | $5.2B | — |
| 000597.SZNortheast Pharmaceutical Group Co., Ltd. | $4.62 | -0.00% | $6.6B | — |
| 000915.SZShandong Wit Dyne Health Co.,Ltd. | $24.25 | -0.25% | $5.7B | — |
| 002030.SZDaan Gene Co., Ltd. | $5.22 | +0.19% | $7.3B | — |
| 002275.SZGuilin Sanjin Pharmaceutical Co., Ltd. |
| $12.12 |
| -0.16% |
| $7.1B |
| — |
| 603229.SSZhejiang Ausun Pharmaceutical Co., Ltd. | $7.55 | -0.13% | $6.3B | — |
| 603590.SSBeijing Konruns Pharmaceutical Co.,Ltd. | $28.41 | +0.18% | $4.5B | — |
Source: Financial Modeling Prep · peers by sector/industry